Grand Rapids, MINCT06723236Now EnrollingIRB Ready

Advanced Solid Tumors Clinical Trial in Grand Rapids, MI

Access cutting-edge advanced solid tumors treatment through this clinical trial at a research site in Grand Rapids. Study-provided care at no cost to qualified participants.

Sponsored by MacroGenics

Quick Self-Assessment

See if you qualify for this Grand Rapids location

Preparing your pre-screening questions…

Expert Care in Grand Rapids

Access advanced solid tumors specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related advanced solid tumors treatment provided free

Apply for This Grand Rapids Location

Check if you qualify for this advanced solid tumors clinical trial in Grand Rapids, MI

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Grand Rapids

    Convenient for MI residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Grand Rapids site if eligible
  4. 4Begin participation

About This Advanced Solid Tumors Study in Grand Rapids

The goal of this clinical trial is to characterize the safety, tolerability, dose-limiting toxicities (DLT), and maximum tolerated dose (MTD) or maximum administered dose of MGC028 (if no MTD is defined). The study will enroll adult participants with relapsed or refractory, unresectable, locally advanced of metastatic solid tumors known to express ADAM9. The main question the study aims to answer is: * What types of side effects will participants experience when receiving MGC028? * Can MGC028 cause cancer to shrink, remain stable, or able to control disease progression of participants with advanced solid tumors? Participants will * Undergo screening procedures to determine eligibility * Receive study treatments initially every 3 weeks. * Have blood samples taken for routine and research tests * Have other examinations to check heart and lung function, and general health status * Be asked about any side effects that may be happening or other medications you are taking. The study doctor will provide treatment for side effects, if necessary. * Have the study doctor assess your tumor status at regular intervals to determine how you are responding to treatment.

Sponsor: MacroGenics

Who Can Participate

Inclusion Criteria

Participants in dose escalation or supplemental cohorts must have histologically proven unresectable, locally advanced or metastatic solid tumor limited to one of the following types: NSCLC adenocarcinoma, cholangiocarcinoma, colorectal carcinoma (CRC), or pancreatic carcinoma that is refractory to standard therapy, or for which standard therapy does not exist, has proven to be intolerable, or has been refused by the participant.
Participants in expansion cohorts must have either
NSCLC adenocarcinoma with
progression on or following anti-PD-1/PD-L1 inhibitor, unless contraindicated
progression on or following therapy for actionable mutations (e.g. EGFR or ALK mutations), if present
no more than 2 prior lines of cytotoxic chemotherapy for advanced or metastatic disease.
Pancreatic cancer
following at least 1 systemic therapy
no more than 2 prior lines of cytotoxic therapy for advanced or metastatic disease.
Colorectal adenocarcinoma with
Progression during or following standard therapy with a fluoropyrimidine-based chemotherapy, oxaliplatin and irinotecan unless contraindicated, refused or unavailable
Progression after prior targeted treatment for CRC with actionable mutations such as EGFR, KRAS, BRAF and MSI- H/dMMR, if present.
No more that 2 lines of cytotoxic chemotherapy for advanced or metastatic disease
No more than 4 lines of systemic regimens for advanced or metastatic disease
Participants must have at least one lesion that meets the definition of measurable disease by RECIST v1.1.
Participants must have an available archival or formalin-fixed paraffin-embedded tumor tissue or be willing to undergo a biopsy procedure to obtain a fresh tumor sample.
Participants have acceptable physical condition and laboratory values.
Participants of childbearing potential must agree to use highly effective methods of birth control.
Participants must not be pregnant, planning to be pregnant, or breastfeeding.

Exclusion Criteria

Any underlying medical or psychiatric condition impairing participant's ability to receive, tolerate, or comply with the planned treatment or study procedures.
Active brain metastases or leptomeningeal metastases.
Prior stem cell, tissue, or solid organ transplant.
Another malignancy that required treatment within the past 2 years, with the exception of those with a negligible risk of metastasis or death such as adequately treated non-melanomatous skin cancer, localized prostate cancer (Gleason Score \< 6), or carcinoma in situ.
Active viral, bacterial, or fungal infection
Prior treatment with ADAM9 targeted agent for cancer.
Prior treatment with major surgery, mediastinal or lung radiation, vaccination with live virus vaccines, systemic cancer treatment, chimeric antigen receptor (CAR)-T cell therapy, or experimental treatment within 4 weeks of the start of study treatment.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Grand Rapids?

Yes, this clinical trial (NCT06723236) has an active research site in Grand Rapids, MI that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Advanced Solid Tumors Treatment Options in Grand Rapids, MI

If you're searching for advanced solid tumors treatment options in Grand Rapids, MI, this clinical trial (NCT06723236) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Grand Rapids research site is actively enrolling participants for this clinical trial. You'll receive care from experienced advanced solid tumors specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all advanced solid tumors clinical trials near you to find additional studies recruiting in your area.

More Advanced Solid Tumors Trials in Grand Rapids, MI

See all advanced solid tumors clinical trials recruiting in Grand Rapids — not just this study.

Browse Advanced Solid Tumors Trials in Grand Rapids →

Browse More Trials by Condition

Advanced Solid Tumors TrialsAlzheimers Disease TrialsAtopic Dermatitis TrialsErectile Dysfunction TrialsAll Conditions →

Ready to Join in Grand Rapids?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Grand Rapids, MI